TScan Therapeutics’ TSC-101 Gains Buy Rating Amid Promising Trial Results and Strategic Focus on Heme Program

Analyst Andres Y. Maldonado of H.C. Wainwright maintained a Buy rating on TScan Therapeutics, retaining the price target of $10.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors including TScan Therapeutics’ recent alignment with the FDA on the pivotal trial design for TSC-101, which provides a clear regulatory pathway for the treatment of AML and MDS. The updated data from the ALLOHA Phase 1 trial, presented in the ASH 2025 abstract, further supports the clinical benefits and manageable safety profile of TSC-101, showing promising results in relapse-free survival and other key metrics.
Despite the strategic decision to pause the solid tumor program, which may initially cause concern in the market, Maldonado views this as a minor setback compared to the strengthened position of TSC-101. The focus on the heme program and manufacturing improvements are seen as positive steps that enhance the consistency and potential success of the therapy. The durability signals and the potential differentiation of TSC-101 in a high unmet need setting contribute to the confidence in its future commercial positioning.